Ad
Thursday, 4 October 2018
J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
Arrowhead Pharmaceuticals Inc said on Thursday Johnson & Johnson would develop and market its gene-silencing Hepatitis B drug and pick up a minor stake in the company in a deal that could be potentially worth more than $3.7 billion.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment